Post-marketing surveillance is crucial for biosimilars due to the potential for rare and long-term adverse effects that may not be detected during pre-approval testing. Continuous monitoring helps in identifying and managing risks associated with the use of biosimilars in diverse patient populations. This ongoing vigilance is vital to maintain patient safety and confidence in biosimilar therapies.
